{
  "symbol": "ABBV",
  "year": 2022,
  "Period": "Q1",
  "report_type": "Q10",
  "metrics": {
    "mdna_sentiment": 0.0,
    "outlook_sentiment": 0.181,
    "forward_ratio": 1.0,
    "hedge_ratio": 0.115
  },
  "top_positive": [
    {
      "sent": "Three months ended September 30, Percent\u00a0change Nine months ended September 30, Percent\u00a0change At\u00a0actual currency\u00a0rates At\u00a0constant currency rates At\u00a0actual currency\u00a0rates At\u00a0constant currency rates (dollars in\u00a0millions) 2022 2021 2022 2021 United States $ 11,763 $ 11,279 4.3 % 4.3 % $ 33,521 $ 31,833 5.3 % 5.3 % International 3,049 3,063 (0.4) % 9.6 % 9,412 9,478 (0.7) % 6.7 % Net revenues $ 14,812 $ 14,342 3.3 % 5.4 % $ 42,933 $ 41,311 3.9 % 5.6 % 2022 Form 10-Q | 29 The following table details AbbVie\u2019s worldwide net revenues: Three months ended September 30, Percent\u00a0change Nine months ended September 30, Percent\u00a0change At\u00a0actual currency rates At\u00a0constant currency rates At\u00a0actual currency rates At\u00a0constant currency rates (dollars in\u00a0millions) 2022 2021 2022 2021 Immunology Humira United States $ 4,956 $ 4,613 7.4 % 7.4 % $ 13,613 $ 12,777 6.5 % 6.5 % International 603 812 (25.9) % (16.8) % 2,045 2,583 (20.9) % (14.3) % Total $ 5,559 $ 5,425 2.5 % 3.9 % $ 15,658 $ 15,360 1.9 % 3.0 % Skyrizi United States $ 1,221 $ 679 79.8 % 79.8 % $ 3,081 $ 1,725 78.6 % 78.6 % International 176 117 50.1 % 70.0 % 508 319 59.3 % 75.1 % Total $ 1,397 $ 796 75.4 % 78.3 % $ 3,589 $ 2,044 75.6 % 78.1 % Rinvoq United States $ 505 $ 348 44.7 % 44.7 % $ 1,228 $ 889 38.0 % 38.0 % International 190 105 82.9 % >100.0 % 524 245 >100.0 % >100.0 % Total $ 695 $ 453 53.5 % 59.3 % $ 1,752 $ 1,134 54.5 % 59.3 % Hematologic Oncology Imbruvica United States $ 849 $ 1,109 (23.5) % (23.5) % $ 2,585 $ 3,207 (19.4) % (19.4) % Collaboration revenues 286 265 7.6 % 7.6 % 868 816 6.3 % 6.3 % Total $ 1,135 $ 1,374 (17.4) % (17.4) % $ 3,453 $ 4,023 (14.2) % (14.2) % Venclexta United States $ 259 $ 237 9.2 % 9.2 % $ 740 $ 685 8.1 % 8.1 % International 256 255 0.1 % 13.2 % 753 647 16.2 % 27.3 % Total $ 515 $ 492 4.5 % 11.3 % $ 1,493 $ 1,332 12.1 % 17.5 % Aesthetics Botox Cosmetic United States $ 370 $ 356 4.1 % 4.1 % $ 1,232 $ 1,027 20.0 % 20.0 % International 267 189 41.0 % 54.5 % 741 579 27.9 % 36.8 % Total $ 637 $ 545 16.9 % 21.6 % $ 1,973 $ 1,606 22.8 % 26.0 % Juvederm Collection United States $ 125 $ 159 (21.9) % (21.9) % $ 420 $ 478 (12.3) % (12.3) % International 227 195 16.9 % 27.7 % 686 625 9.9 % 17.6 % Total $ 352 $ 354 (0.6) % 5.3 % $ 1,106 $ 1,103 0.3 % 4.6 % Other Aesthetics United States $ 265 $ 305 (13.1) % (13.1) % $ 837 $ 968 (13.4) % (13.4) % International 47 47 (0.8) % 8.3 % 130 149 (12.8) % (7.2) % Total $ 312 $ 352 (11.4) % (10.2) % $ 967 $ 1,117 (13.4) % (12.7) % Neuroscience Botox Therapeutic United States $ 584 $ 534 9.2 % 9.2 % $ 1,641 $ 1,451 13.1 % 13.1 % International 115 111 3.6 % 14.2 % 350 329 6.5 % 15.0 % Total $ 699 $ 645 8.2 % 10.0 % $ 1,991 $ 1,780 11.9 % 13.5 % Vraylar United States $ 554 $ 461 20.1 % 20.1 % $ 1,473 $ 1,239 18.9 % 18.9 % Duodopa United States $ 22 $ 23 (4.9) % (4.9) % $ 72 $ 73 (2.4) % (2.4) % International 88 104 (15.0) % (2.6) % 279 310 (9.8) % \u2014 % Total $ 110 $ 127 (13.1) % (3.0) % $ 351 $ 383 (8.4) % (0.5) % Ubrelvy United States $ 160 $ 162 (1.4) % (1.4) % $ 483 $ 369 31.0 % 31.0 % Qulipta United States $ 62 $ \u2014 n/m n/m $ 106 $ \u2014 n/m n/m Other Neuroscience United States $ 82 $ 166 (50.5) % (50.5) % $ 400 $ 489 (18.3) % (18.3) % International 5 5 10.2 % 14.1 % 14 13 10.3 % 13.1 % Total $ 87 $ 171 (49.0) % (48.9) % $ 414 $ 502 (17.6) % (17.5) % 2022 Form 10-Q | 30 Three months ended September 30, Percent\u00a0change Nine months ended September 30, Percent\u00a0change At\u00a0actual currency rates At\u00a0constant currency rates At\u00a0actual currency rates At\u00a0constant currency rates (dollars in\u00a0millions) 2022 2021 2022 2021 Eye Care Lumigan/Ganfort United States $ 59 $ 63 (4.4) % (4.4) % $ 186 $ 201 (7.1) % (7.1) % International 62 75 (18.7) % (8.7) % 205 229 (10.8) % (2.9) % Total $ 121 $ 138 (12.2) % (6.7) % $ 391 $ 430 (9.0) % (4.8) % Alphagan/Combigan United States $ 37 $ 89 (58.2) % (58.2) % $ 161 $ 271 (40.8) % (40.8) % International 36 39 (8.9) % 2.9 % 111 117 (5.1) % 4.9 % Total $ 73 $ 128 (43.0) % (39.4) % $ 272 $ 388 (30.0) % (27.0) % Restasis United States $ 132 $ 305 (56.7) % (56.7) % $ 518 $ 884 (41.3) % (41.3) % International 10 14 (30.7) % (37.7) % 38 42 (10.1) % (2.8) % Total $ 142 $ 319 (55.6) % (55.9) % $ 556 $ 926 (39.9) % (39.6) % Other Eye Care United States $ 134 $ 128 3.7 % 3.7 % $ 400 $ 375 6.3 % 6.3 % International 153 158 (2.7) % 9.1 % 492 488 0.9 % 10.1 % Total $ 287 $ 286 0.1 % 6.6 % $ 892 $ 863 3.3 % 8.5 % Other Key Products Mavyret United States $ 190 $ 183 3.5 % 3.5 % $ 562 $ 557 0.9 % 0.9 % International 193 243 (20.6) % (10.3) % 599 726 (17.5) % (9.1) % Total $ 383 $ 426 (10.2) % (4.4) % $ 1,161 $ 1,283 (9.5) % (4.7) % Creon United States $ 336 $ 310 8.5 % 8.5 % $ 941 $ 864 9.0 % 9.0 % Linzess/Constella United States $ 262 $ 253 3.4 % 3.4 % $ 742 $ 728 2.0 % 2.0 % International 9 8 16.0 % 25.8 % 24 23 3.2 % 9.6 % Total $ 271 $ 261 3.8 % 4.1 % $ 766 $ 751 2.0 % 2.2 % All other $ 925 $ 1,117 (16.8) % (15.3) % $ 3,145 $ 3,814 (17.5) % (16.3) % Total net revenues $ 14,812 $ 14,342 3.3 % 5.4 % $ 42,933 $ 41,311 3.9 % 5.6 % n/m \u2013 Not meaningful The following discussion and analysis of AbbVie\u2019s net revenues by product is presented on a constant currency basis.",
      "score": 0.996
    },
    {
      "sent": "AbbVie intends to continue to advance its mission in a number of ways, including: (i) maximizing the benefits of a diversified revenue base with multiple long-term growth drivers; (ii)\u00a0growing revenues by leveraging AbbVie's commercial strength and international infrastructure across therapeutic areas and ensuring strong commercial execution of new product launches; (iii)\u00a0continuing to invest in and expand its pipeline in support of opportunities in immunology, oncology, aesthetics, neuroscience and eye care as well as continued investment in key on-market products; (iv)\u00a0expanding operating margins; and (v)\u00a0returning cash to shareholders via a strong and growing dividend while also reducing debt.",
      "score": 0.9803
    },
    {
      "sent": "AbbVie\u2019s long-term success depends to a great extent on its ability to continue to discover and develop innovative products and acquire or collaborate on compounds currently in development by other biotechnology or pharmaceutical companies.",
      "score": 0.9186
    }
  ],
  "top_negative": [
    {
      "sent": "Further, because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that misstatements due to error or fraud will not occur or that all control issues and instances of fraud, if any, have been detected.",
      "score": -0.8779
    },
    {
      "sent": "Further, because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that misstatements due to error or fraud will not occur or that all control issues and instances of fraud, if any, have been detected.",
      "score": -0.8779
    },
    {
      "sent": "Further, because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that misstatements due to error or fraud will not occur or that all control issues and instances of fraud, if any, have been detected.",
      "score": -0.8779
    }
  ],
  "forward_snippets": [
    "AbbVie intends to continue to advance its mission in a number of ways, including: (i) maximizing the benefits of a diversified revenue base with multiple long-term growth drivers; (ii)\u00a0growing revenues by leveraging AbbVie's commercial strength and international infrastructure across therapeutic areas and ensuring strong commercial execution of new product launches; (iii)\u00a0continuing to invest in and expand its pipeline in support of opportunities in immunology, oncology, aesthetics, neuroscience and eye care as well as continued investment in key on-market products; (iv)\u00a0expanding operating margins; and (v)\u00a0returning cash to shareholders via a strong and growing dividend while also reducing debt.",
    "Additionally, financial results reflected continued funding to support all stages of AbbVie\u2019s pipeline assets and continued investment in AbbVie\u2019s on-market brands.",
    "Throughout the pandemic, AbbVie has followed health and safety guidance from state and local health authorities and implemented safety measures for those employees who are returning to the workplace.",
    "AbbVie\u2019s pipeline currently includes approximately 80 compounds, devices or indications in development individually or under collaboration or license agreements and is focused on such important specialties as immunology, oncology, aesthetics, neuroscience and eye care.",
    "Additionally, financial results reflected continued funding to support all stages of AbbVie\u2019s pipeline assets and continued investment in AbbVie\u2019s on-market brands."
  ],
  "curated_text": "Symbol: ABBV. Year: 2022. Period: Q1. ReportType: Q10. Section: Management Discussion and Analysis (MD&A). Key metrics include sentiment, forward outlook, and risk hedging.  Top positive sentences: Three months ended September 30, Percent\u00a0change Nine months ended September 30, Percent\u00a0change At\u00a0actual currency\u00a0rates At\u00a0constant currency rates At\u00a0actual currency\u00a0rates At\u00a0constant currency rates (dollars in\u00a0millions) 2022 2021 2022 2021 United States $ 11,763 $ 11,279 4.3 % 4.3 % $ 33,521 $ 31,833 5.3 % 5.3 % International 3,049 3,063 (0.4) % 9.6 % 9,412 9,478 (0.7) % 6.7 % Net revenues $ 14,812 $ 14,342 3.3 % 5.4 % $ 42,933 $ 41,311 3.9 % 5.6 % 2022 Form 10-Q | 29 The following table details AbbVie\u2019s worldwide net revenues: Three months ended September 30, Percent\u00a0change Nine months ended September 30, Percent\u00a0change At\u00a0actual currency rates At\u00a0constant currency rates At\u00a0actual currency rates At\u00a0constant currency rates (dollars in\u00a0millions) 2022 2021 2022 2021 Immunology Humira United States $ 4,956 $ 4,613 7.4 % 7.4 % $ 13,613 $ 12,777 6.5 % 6.5 % International 603 812 (25.9) % (16.8) % 2,045 2,583 (20.9) % (14.3) % Total $ 5,559 $ 5,425 2.5 % 3.9 % $ 15,658 $ 15,360 1.9 % 3.0 % Skyrizi United States $ 1,221 $ 679 79.8 % 79.8 % $ 3,081 $ 1,725 78.6 % 78.6 % International 176 117 50.1 % 70.0 % 508 319 59.3 % 75.1 % Total $ 1,397 $ 796 75.4 % 78.3 % $ 3,589 $ 2,044 75.6 % 78.1 % Rinvoq United States $ 505 $ 348 44.7 % 44.7 % $ 1,228 $ 889 38.0 % 38.0 % International 190 105 82.9 % >100.0 % 524 245 >100.0 % >100.0 % Total $ 695 $ 453 53.5 % 59.3 % $ 1,752 $ 1,134 54.5 % 59.3 % Hematologic Oncology Imbruvica United States $ 849 $ 1,109 (23.5) % (23.5) % $ 2,585 $ 3,207 (19.4) % (19.4) % Collaboration revenues 286 265 7.6 % 7.6 % 868 816 6.3 % 6.3 % Total $ 1,135 $ 1,374 (17.4) % (17.4) % $ 3,453 $ 4,023 (14.2) % (14.2) % Venclexta United States $ 259 $ 237 9.2 % 9.2 % $ 740 $ 685 8.1 % 8.1 % International 256 255 0.1 % 13.2 % 753 647 16.2 % 27.3 % Total $ 515 $ 492 4.5 % 11.3 % $ 1,493 $ 1,332 12.1 % 17.5 % Aesthetics Botox Cosmetic United States $ 370 $ 356 4.1 % 4.1 % $ 1,232 $ 1,027 20.0 % 20.0 % International 267 189 41.0 % 54.5 % 741 579 27.9 % 36.8 % Total $ 637 $ 545 16.9 % 21.6 % $ 1,973 $ 1,606 22.8 % 26.0 % Juvederm Collection United States $ 125 $ 159 (21.9) % (21.9) % $ 420 $ 478 (12.3) % (12.3) % International 227 195 16.9 % 27.7 % 686 625 9.9 % 17.6 % Total $ 352 $ 354 (0.6) % 5.3 % $ 1,106 $ 1,103 0.3 % 4.6 % Other Aesthetics United States $ 265 $ 305 (13.1) % (13.1) % $ 837 $ 968 (13.4) % (13.4) % International 47 47 (0.8) % 8.3 % 130 149 (12.8) % (7.2) % Total $ 312 $ 352 (11.4) % (10.2) % $ 967 $ 1,117 (13.4) % (12.7) % Neuroscience Botox Therapeutic United States $ 584 $ 534 9.2 % 9.2 % $ 1,641 $ 1,451 13.1 % 13.1 % International 115 111 3.6 % 14.2 % 350 329 6.5 % 15.0 % Total $ 699 $ 645 8.2 % 10.0 % $ 1,991 $ 1,780 11.9 % 13.5 % Vraylar United States $ 554 $ 461 20.1 % 20.1 % $ 1,473 $ 1,239 18.9 % 18.9 % Duodopa United States $ 22 $ 23 (4.9) % (4.9) % $ 72 $ 73 (2.4) % (2.4) % International 88 104 (15.0) % (2.6) % 279 310 (9.8) % \u2014 % Total $ 110 $ 127 (13.1) % (3.0) % $ 351 $ 383 (8.4) % (0.5) % Ubrelvy United States $ 160 $ 162 (1.4) % (1.4) % $ 483 $ 369 31.0 % 31.0 % Qulipta United States $ 62 $ \u2014 n/m n/m $ 106 $ \u2014 n/m n/m Other Neuroscience United States $ 82 $ 166 (50.5) % (50.5) % $ 400 $ 489 (18.3) % (18.3) % International 5 5 10.2 % 14.1 % 14 13 10.3 % 13.1 % Total $ 87 $ 171 (49.0) % (48.9) % $ 414 $ 502 (17.6) % (17.5) % 2022 Form 10-Q | 30 Three months ended September 30, Percent\u00a0change Nine months ended September 30, Percent\u00a0change At\u00a0actual currency rates At\u00a0constant currency rates At\u00a0actual currency rates At\u00a0constant currency rates (dollars in\u00a0millions) 2022 2021 2022 2021 Eye Care Lumigan/Ganfort United States $ 59 $ 63 (4.4) % (4.4) % $ 186 $ 201 (7.1) % (7.1) % International 62 75 (18.7) % (8.7) % 205 229 (10.8) % (2.9) % Total $ 121 $ 138 (12.2) % (6.7) % $ 391 $ 430 (9.0) % (4.8) % Alphagan/Combigan United States $ 37 $ 89 (58.2) % (58.2) % $ 161 $ 271 (40.8) % (40.8) % International 36 39 (8.9) % 2.9 % 111 117 (5.1) % 4.9 % Total $ 73 $ 128 (43.0) % (39.4) % $ 272 $ 388 (30.0) % (27.0) % Restasis United States $ 132 $ 305 (56.7) % (56.7) % $ 518 $ 884 (41.3) % (41.3) % International 10 14 (30.7) % (37.7) % 38 42 (10.1) % (2.8) % Total $ 142 $ 319 (55.6) % (55.9) % $ 556 $ 926 (39.9) % (39.6) % Other Eye Care United States $ 134 $ 128 3.7 % 3.7 % $ 400 $ 375 6.3 % 6.3 % International 153 158 (2.7) % 9.1 % 492 488 0.9 % 10.1 % Total $ 287 $ 286 0.1 % 6.6 % $ 892 $ 863 3.3 % 8.5 % Other Key Products Mavyret United States $ 190 $ 183 3.5 % 3.5 % $ 562 $ 557 0.9 % 0.9 % International 193 243 (20.6) % (10.3) % 599 726 (17.5) % (9.1) % Total $ 383 $ 426 (10.2) % (4.4) % $ 1,161 $ 1,283 (9.5) % (4.7) % Creon United States $ 336 $ 310 8.5 % 8.5 % $ 941 $ 864 9.0 % 9.0 % Linzess/Constella United States $ 262 $ 253 3.4 % 3.4 % $ 742 $ 728 2.0 % 2.0 % International 9 8 16.0 % 25.8 % 24 23 3.2 % 9.6 % Total $ 271 $ 261 3.8 % 4.1 % $ 766 $ 751 2.0 % 2.2 % All other $ 925 $ 1,117 (16.8) % (15.3) % $ 3,145 $ 3,814 (17.5) % (16.3) % Total net revenues $ 14,812 $ 14,342 3.3 % 5.4 % $ 42,933 $ 41,311 3.9 % 5.6 % n/m \u2013 Not meaningful The following discussion and analysis of AbbVie\u2019s net revenues by product is presented on a constant currency basis. AbbVie intends to continue to advance its mission in a number of ways, including: (i) maximizing the benefits of a diversified revenue base with multiple long-term growth drivers; (ii)\u00a0growing revenues by leveraging AbbVie's commercial strength and international infrastructure across therapeutic areas and ensuring strong commercial execution of new product launches; (iii)\u00a0continuing to invest in and expand its pipeline in support of opportunities in immunology, oncology, aesthetics, neuroscience and eye care as well as continued investment in key on-market products; (iv)\u00a0expanding operating margins; and (v)\u00a0returning cash to shareholders via a strong and growing dividend while also reducing debt. AbbVie\u2019s long-term success depends to a great extent on its ability to continue to discover and develop innovative products and acquire or collaborate on compounds currently in development by other biotechnology or pharmaceutical companies. Top negative sentences: Further, because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that misstatements due to error or fraud will not occur or that all control issues and instances of fraud, if any, have been detected. Further, because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that misstatements due to error or fraud will not occur or that all control issues and instances of fraud, if any, have been detected. Further, because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that misstatements due to error or fraud will not occur or that all control issues and instances of fraud, if any, have been detected. Forward-looking snippets: AbbVie intends to continue to advance its mission in a number of ways, including: (i) maximizing the benefits of a diversified revenue base with multiple long-term growth drivers; (ii)\u00a0growing revenues by leveraging AbbVie's commercial strength and international infrastructure across therapeutic areas and ensuring strong commercial execution of new product launches; (iii)\u00a0continuing to invest in and expand its pipeline in support of opportunities in immunology, oncology, aesthetics, neuroscience and eye care as well as continued investment in key on-market products; (iv)\u00a0expanding operating margins; and (v)\u00a0returning cash to shareholders via a strong and growing dividend while also reducing debt. Additionally, financial results reflected continued funding to support all stages of AbbVie\u2019s pipeline assets and continued investment in AbbVie\u2019s on-market brands. Throughout the pandemic, AbbVie has followed health and safety guidance from state and local health authorities and implemented safety measures for those employees who are returning to the workplace. AbbVie\u2019s pipeline currently includes approximately 80 compounds, devices or indications in development individually or under collaboration or license agreements and is focused on such important specialties as immunology, oncology, aesthetics, neuroscience and eye care. Additionally, financial results reflected continued funding to support all stages of AbbVie\u2019s pipeline assets and continued investment in AbbVie\u2019s on-market brands."
}